Skip to content

Helping patients reclaim a life of possibility

Menu
  • About us
  • Contact us
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
      • Member and patient community programmes
        • Myeloma Awareness Month
        • MPE Masterclass
        • Scholarship programme
        • Care Connect Programme
        • Myeloma CABs
        • MPE Myeloma and AL amyloidosis Community Taskforce
        • Advocate Development Programme
        • European Young Myeloma Patients Group
        • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • Research
        • Patient Evidence
        • Horizon Europe
        • IMI
      • Access and Policy
        • Myeloma Access Atlas
        • CEE workgroup on Access
        • Myeloma and AL amyloidosis Clinical Trial Navigator
        • EU HTA regulation
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • European Myeloma Day
  • News
logo MPE
Charlotte Haynes

CHARLOTTE HAYNES

Charlotte joined MPE as Scientific and Patient Information Manager in January 2026.

Charlotte holds a PhD and BSc in Experimental Psychology from the University of Sussex, and a Postgraduate Certificate in Public Health from the University of Manchester. She has over 20 years of experience in healthcare research, evidence synthesis, and scientific communication.

Before joining MPE, Charlotte worked for 13 years at the National Institute for Health and Care Excellence (NICE), a public body that develops independent, evidence-based guidance to improve health and social care in England. She also worked for eight years as Research and Projects Lead at a UK NHS foundation trust hospital. In these roles, she worked at the interface of science, policy, and communication, ensuring that evidence was accurately interpreted and translated into clear, practical recommendations for health and social care professionals, commissioners and managers, patients, service users and carers.

Charlotte has a strong commitment to patient-centred communication and to ensuring that information is inclusive and accessible for all patient populations. She currently lives in the North West of England. She speaks English fluently and French at an upper-intermediate level.

 

Recent Posts

Image (7)

Israel Amyloidosis Association highlights innovation and patient support at annual conference

28 October 2026

The Israel Amyloidosis Association held its annual conference on 23 October 2026, bringing together approximately 200 patients, clinicians and researchers from across Israel. The event took place just ahead of…

Read more
ISA 2026 highlights webinar

MPE webinar | International Symposium on Amyloidosis (ISA 2026) highlights

28 October 2026

Myeloma Patients Europe (MPE) will host a webinar the “ International Symposium on Amyloidosis (ISA 2026) highlights”, on Wednesday, 25 November 2026 at 17:00 CET. During this webinar, you will…

Read more

Amen Association promotes shared decision-making across Israel

27 October 2026

Recently, AMEN Association, one of Myeloma Patients Europe’s (MPE) member organisations in Israel, carried out its “Changing Direction” campaign to help people living with myeloma and their families better understand…

Read more
EMAs CHMP positive opinion image

EMA committee recommends new talquetamab treatment combinations for relapsed or refractory myeloma

27 October 2026

On 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®) to include combinations with daratumumab, either alone or together…

Read more
Amyloidosis pathway cover

World Amyloidosis Day: help your doctor spot AL amyloidosis sooner

23 October 2026

World Amyloidosis Day is 26 October. To mark the day, MPE is asking everyone in our community to download the MPE Amyloidosis Diagnosis Pathway and share it with their GP…

Read more
Screenshot 2026 10 02 112724

MPE members drive myeloma awareness across Europe during EMD and BCAM

6 October 2026

September proved to be an extraordinary month for myeloma advocacy across MPE’s member network. Our members delivered bold, impactful campaigns to raise awareness during Blood Cancer Awareness Month (BCAM) and…

Read more
mpe logo negativo 300x249 1

Myeloma Patients Europe AISBL

Avenue Louise 143/4, 1050
Brussels Belgium
© Myeloma Patients Europe 2026
  • Contact
  • About us
  • Privacy policy
  • Terms and conditions
  • Cookies Policy
Go to Top
logo MPE
  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Committee
    • Our Strategic Goals
    • Our funding
    • Get involved in MPE activities
    • Become a member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • Myeloma Awareness Month
      • MPE Masterclass
      • Scholarship programme
      • Care Connect Programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • European Young Myeloma Patients Group
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access and Policy
      • Myeloma Access Atlas
      • CEE workgroup on Access
      • Myeloma and AL amyloidosis Clinical Trial Navigator
      • EU HTA regulation
  • Educational Resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Patient guides
  • News
  • European Myeloma Day

PopUp

  • This field is for validation purposes and should be left unchanged.